Cancer genomics and NGS workflowsprimary
2 projects
Instand-NGS4P involved standardized next-generation sequencing for personalised therapy; PERSIST-SEQ applies single-cell sequencing to study therapeutic resistance.
Organization
FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA
Italian oncology research centre specialising in cancer genomics, AI-driven imaging, and single-cell technologies for precision medicine.
Research institutehealthIT
H2020 projects
4
As coordinator
1
Total EC funding
€1.1M
Unique partners
59
What they do
Their core work
FPO is an Italian oncology research foundation based in Candiolo (Turin), operating the Candiolo Cancer Institute (IRCC). They focus on understanding cancer biology at the molecular and cellular level, with particular strength in colorectal and prostate cancer research. Their work spans from fundamental cancer metabolism studies to applied clinical tools — including AI-driven imaging platforms for precision oncology and single-cell sequencing to understand why tumours resist treatment. They bridge laboratory research with clinical translation, contributing genomic and imaging data to large European cancer initiatives.
Core expertise
What they specialise in
AI-driven medical imaging for oncologyprimary
1 project
ProCAncer-I builds an AI platform integrating prostate cancer imaging data with cloud infrastructure and advanced AI techniques — their largest funded project (EUR 865K).
Cancer metabolism and tumour biologysecondary
2 projects
MDCRC studied metabolic dynamics in colorectal cancer; PERSIST-SEQ investigates tumour cell persistence using spatial and single-cell transcriptomics.
Single-cell and spatial omicsemerging
1 project
PERSIST-SEQ explicitly targets single-cell sequencing, spatial transcriptomics, single-cell epigenomics, and patient-derived organoids/xenografts.
Pharmacogenetics and personalised therapysecondary
1 project
Instand-NGS4P covers pharmacogenetics, gene panels, e-medication, and e-reporting for treatment personalisation.
Evolution & trajectory
How they've shifted over time
Early focus
Cancer genomics and sequencing standards
Recent focus
AI imaging and single-cell omics
FPO's early H2020 work (2018–2020) centred on cancer metabolism and standardised genomic sequencing workflows — establishing foundational molecular oncology capabilities. Their more recent projects (2020–2026) show a clear pivot toward data-intensive and computational approaches: AI-powered imaging platforms, cloud infrastructure, and single-cell multi-omics. This trajectory mirrors the broader shift in oncology from bulk molecular profiling toward spatially resolved, AI-augmented precision medicine.
FPO is moving decisively toward computational oncology — combining AI, cloud platforms, and single-cell resolution data — making them an increasingly relevant partner for digital health and precision medicine consortia.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European18 countries collaborated
FPO primarily operates as a specialist contributor within large European consortia rather than leading them — they coordinated only one smaller Marie Curie fellowship (MDCRC) while participating in much larger multi-partner projects. With 59 unique partners across 18 countries from just 4 projects, they are embedded in broad international networks, suggesting they are sought out for their specific cancer research capabilities. Their one third-party role in Instand-NGS4P also indicates they provide specialised services (likely genomic/pathology expertise) to consortia they don't formally belong to.
Despite only 4 H2020 projects, FPO has built a remarkably wide network of 59 unique partners across 18 countries, reflecting the large consortia typical of health research. Their partnerships span across Europe with no obvious geographic concentration beyond Italy.
Why partner with them
What sets them apart
FPO sits at the intersection of clinical oncology, molecular genomics, and AI — a combination that few single institutions cover. Their Candiolo Cancer Institute provides direct access to patient-derived models (organoids, xenografts) and clinical imaging data, which are critical bottlenecks for AI training in oncology. For consortium builders, they offer a rare package: a cancer-focused research centre that can contribute both wet-lab biological data and computational/AI readiness.
Notable projects
Highlights from their portfolio
- ProCAncer-ILargest funded project (EUR 865K) building an AI platform for prostate cancer imaging — represents FPO's move into digital health and their biggest financial stake in H2020.
- PERSIST-SEQApplies frontier single-cell and spatial omics technologies to understand why cancer cells survive treatment — signals FPO's emerging expertise direction.
- Instand-NGS4PLarge-scale PCP project standardising NGS workflows across Europe for personalised therapy — FPO contributes as a third party, indicating recognised domain authority.
Cross-sector capabilities
Digital health and AI-driven diagnosticsCloud infrastructure for medical data platformsBioinformatics and computational biologyStandardisation and quality assurance for genomic testing
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →